Cargando…

Integration of RNA-Seq and Machine Learning Identifies Hub Genes for Empagliflozin Benefitable Heart Failure with Reduced Ejection Fraction

PURPOSE: This study aimed to analyze the hub genes of heart failure with reduced ejection fraction (HFrEF) treated with Empagliflozin using RNA sequencing (RNA-seq) and bioinformatics methods, including machine learning. METHODS: From February 2021 to February 2023, nine patients with HFrEF were enr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Qiang, Gao, Jing, Wang, Tian-Yu, Ding, Jun-Can, Hu, Peng-Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590560/ https://www.ncbi.nlm.nih.gov/pubmed/37872956 http://dx.doi.org/10.2147/JIR.S429096

Ejemplares similares

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
por: Sciatti, Edoardo, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
por: Kolovos, Spyros, et al.
Publicado: (2023)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
por: Kolovos, Spyros, et al.
Publicado: (2023)

Identification of Key Immune-Related Genes in the Treatment of Heart Failure After Myocardial Infarction with Empagliflozin Based on RNA-Seq
por: Zhang, Pei, et al.
Publicado: (2023)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
por: Liang, Bo, et al.
Publicado: (2020)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
por: Tang, Yi, et al.
Publicado: (2022)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
por: Tafazzoli, Ali, et al.
Publicado: (2022)

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
por: Packer, Milton, et al.
Publicado: (2021)

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction
por: Connelly, Kim A., et al.
Publicado: (2019)

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
por: Jensen, Jesper, et al.
Publicado: (2019)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
por: Kim, Inho, et al.
Publicado: (2023)

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
por: Connelly, Kim A., et al.
Publicado: (2020)

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2021)

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
por: Packer, Milton, et al.
Publicado: (2020)

A Systematic Review Exploring the Cardiovascular and Renal Effects of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction
por: Athiyaman, Sreekartthik, et al.
Publicado: (2022)

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Lam, Carolyn S P, et al.
Publicado: (2021)

Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective
por: Lin, Xiaohui, et al.
Publicado: (2022)

Myocardial strain to identify benefit from beta‐blockers in patients with heart failure with reduced ejection fraction
por: Park, Chan Soon, et al.
Publicado: (2022)

Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
por: Jiang, Yaohui, et al.
Publicado: (2022)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
por: Anker, Stefan D., et al.
Publicado: (2022)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Machine Learning for Mortality Prediction in Patients With Heart Failure With Mildly Reduced Ejection Fraction
por: Tian, Pengchao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_blsvbahe9463oee9qcccvuc9rj